HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platforms, announced the closing of a new financing round with participation from Reed Jobs and Yosemite, whose aim is to “make cancer non-lethal in our lifetime,” alongside several new strategic investors. Additional financing terms were not disclosed.
The financing comes amid significant momentum for HistoSonics as the company continues to expand clinical adoption of histotripsy for liver tumors around the world and is quickly advancing additional applications of its non-invasive platform across solid tumors.
Histotripsy is a non-invasive therapeutic platform that uses focused ultrasound energy and acoustic cavitation to mechanically destroy targeted tissue without surgery or radiation, and with potentially fewer side effects than traditional therapies. The Edison Histotripsy System received U.S. FDA De Novo clearance for the destruction of liver tumors and has since seen expanding clinical adoption across the United States and internationally. Use of the Edison Histotripsy System in applications outside of the liver is limited to investigational use.
Synektik Group is the sole distributor of Edison in Poland, the Czech Republic, Slovakia, Lithuania, Latvia and Estonia.
